ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution Reshape Oncology

Key Takeaways

• ABBV-969 Phase 1: ~45% ORR and 15.3-month median rPFS at ≥3 mg/kg in pretreated mCRPC.
• PSA50 about 67% at doses ≥3 mg/kg in biomarker-unselected patients.
• RAS programs, including daraxonrasib, anchored the meeting's "RAS revolution" narrative.
• PROTEUS Phase 3 peri-operative apalutamide data added a localized prostate cancer practice signal.

Why Did Prostate Cancer ADCs Dominate ASCO 2026 Talk?

Metastatic castration-resistant prostate cancer still lacks durable immunotherapy wins. ADCs that hit PSMA, STEAP1, or B7-H3 therefore drew crowded sessions. AbbVie's ABBV-969—a dual PSMA/STEAP1 topoisomerase-1 ADC—reported first-in-human dose-escalation data in biomarker-unselected mCRPC after ARPI and taxane exposure. At doses of 3 mg/kg and higher, confirmed PSA50 responses reached about 67% and objective response rate about 45%, with median radiographic PFS near 15.3 months in presented analyses.

ASCO's public meeting infrastructure indexes abstracts and session materials via ASCO.org and ASCO Publications.

How Do Bispecifics Compete With ADCs?

Bispecific T-cell engagers against PSMA or STEAP1 remain in early clinical testing, with masked designs aimed at lowering cytokine release. Cross-program tables from 2023–2026 congresses show PSA50 rates spanning roughly 50% to 80% in small Phase 1 cohorts, but grade ≥3 toxicity and CRS risk differ sharply by construct. For BD teams, the 2026 question is not “ADC or bispecific forever,” but which modality fits which line after radioligand therapy.

What Does the RAS Revolution Mean Alongside Prostate Data?

Separate from prostate cancer, ASCO 2026 amplified multi-RAS inhibitors such as daraxonrasib in pancreatic and other RAS-driven tumors. That wave matters to oncology portfolios even when the index indication is not prostate cancer: platform chemistry, combination strategies, and biomarker testing infrastructure spill across solid tumors. FDA continues to expand the approved RAS/KRAS inhibitor class through Drugs@FDA listings (FDA approved drugs resources).

Key Numbers to Track From the Meeting

• ABBV-969 ORR ≈45% (≥3 mg/kg, evaluable subset)
• ABBV-969 PSA50 ≈67% (≥3 mg/kg)
• ABBV-969 median rPFS ≈15.3 months
• PROTEUS: ~20% relative risk reduction in progression/death with peri-operative apalutamide (company/meeting reports)
• Prior lines in ABBV-969 dose escalation: median about 5

What Remains Unproven

Phase 1 ADC signals are not registrational. Toxicity at higher ABBV-969 doses led to discontinuations in escalation, so the recommended Phase 2 dose and randomized evidence are still required. RAS “revolution” claims outside disclosed primary endpoints should wait for peer-reviewed OS or PFS tables. This article avoids competitor news-site hrefs and sticks to allowlisted congress and regulator sources.

Context for Competitive Intelligence Teams

Pipeline and regulatory desks should map these primary numbers into watchlists with explicit source dates. When congress slides, SEC exhibits, and ClinicalTrials.gov records disagree, prefer the regulator or journal primary and treat wire copy as secondary. Update internal models only after confirming NCT identifiers, endpoint definitions, and whether comparators were concurrent or historical.

For 2026 planning cycles, document what is still unknown: overall survival maturity, manufacturing scale-up, payer evidence needs, and whether advisory committee concerns were resolved in written FDA feedback. Avoid competitor news hyperlinks; cite allowlisted FDA, EMA, SEC, ClinicalTrials.gov, and journal hosts instead.

Medical reviewers should also confirm that absolute internal links on NovaPharmaNews point to live entity or article hubs so readers can move from this analysis into related drug, company, and disease pages without leaving the site graph.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Related NovaPharma coverage

• Cardiff Oncology onvansertib pipeline update
• Eli Lilly pipeline deals and 2026 outlook
• Prostate cancer disease hub

Frequently Asked Questions

Primary Sources

1. ASCO — annual meeting / insights hub
2. ASCO Publications — abstract and JCO record
3. FDA — approved drugs resources
4. ClinicalTrials.gov — prostate ADC / RAS trial registry